Latest Stocks: Kura Oncology Inc (KURA) to Post FY2020 Earnings of $4.26 Per Share, Oppenheimer Holdings Forecasts

Latest Stocks: Kura Oncology Inc (KURA) to Post FY2020 Earnings of $4.26 Per Share, Oppenheimer Holdings Forecasts

A number of other equities research analysts have also recently commented on KURA. Cann reissued an “outperform” rating and issued a $18.00 target price on shares of Kura Oncology in a research note on Monday, March 6th. Zacks Investment Research raised Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 12th.

Kura Oncology Inc (NASDAQ:KURA) – Equities researchers at Oppenheimer Holdings decreased their FY2020 earnings per share estimates for shares of Kura Oncology in a research note issued to investors on Monday. Oppenheimer Holdings analyst L. Cann now expects that the company will post earnings of $4.26 per share for the year, down from their previous estimate of $4.33. Oppenheimer Holdings has a “Outperform” rating and a $16.00 price objective on the stock. Oppenheimer Holdings also issued estimates for Kura Oncology’s FY2021 earnings at $6.70 EPS.

A number of other equities research analysts have also recently commented on KURA. Cann reissued an “outperform” rating and issued a $18.00 target price on shares of Kura Oncology in a research note on Monday, March 6th. Zacks Investment Research raised Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 12th. Shares of Kura Oncology (NASDAQ:KURA) traded down 1.389% during trading on Wednesday, hitting $8.875. 7,831 shares of the stock traded hands. The company’s market cap is $171.70 million. Kura Oncology has a 52 week low of $2.50 and a 52 week high of $12.10. The firm’s 50-day moving average price is $9.61 and its 200-day moving average price is $7.25.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Monday, May 15th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.05. Large investors have recently added to or reduced their stakes in the company. Partner Investment Management L.P. boosted its stake in Kura Oncology by 2.7% in the third quarter. Partner Investment Management L.P. now owns 23,646 shares of the company’s stock worth $148,000 after buying an additional 623 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Kura Oncology by 25.4% in the fourth quarter. Renaissance Technologies LLC now owns 30,600 shares of the company’s stock worth $181,000 after buying an additional 6,200 shares in the last quarter. First Republic Investment Management Inc. bought a new stake in Kura Oncology during the fourth quarter worth approximately $174,000. Nationwide Fund Advisors bought a new stake in Kura Oncology during the first quarter worth approximately $136,000. Finally, Alethea Capital Management LLC boosted its stake in Kura Oncology by 31.8% in the first quarter. Alethea Capital Management LLC now owns 84,769 shares of the company’s stock worth $746,000 after buying an additional 20,469 shares in the last quarter. 45.73% of the stock is currently owned by hedge funds and other institutional investors.

About Kura Oncology Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Receive News & Ratings for Kura Oncology Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Kura Oncology Inc and related companies with our FREE daily email newsletter.

Related posts

Leave a Comment